Multiple Dose Rhenium-186 NanoLiposome for Leptomeningeal Metastases
This study is testing a new treatment called Rhenium-186 NanoLiposome (186RNL) for people with leptomeningeal metastases (LM), which is when cancer spreads to the fluid and tissues surrounding the brain and spinal cord. The treatment is given directly into the fluid around the brain. Researchers want to find the safest and most effective dose of 186RNL, how it spreads in the body, and if it is safe to give multiple doses. You may be able to join if you are at least 18 years old, have LM from any solid tumor cancer, and meet certain health requirements. This study is currently open, but its recruitment status is unclear.
- Study design
- This is an open-label, multi-center Phase 1 study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 24 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main safety and dose distribution are measured for 13 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
At a glance
Conditions
NCT07098806
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The Cancer Therapy and Research Center at UTHSCSA
San Antonio, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Maximum Tolerated Dose13 months
Evaluation of any toxicity associated with research treatment per Common Criteria for Adverse Events.
- Dose Distribution of 186RNL13 months
SPECT imaging of the radioactive materials spread in the Cerebrospinal Fluid.
- Safety and tolerability of multiple dose treatment13 months
Evaluation of any toxicity associated with research treatment as determined by National Cancer Institute (NCI) common Terminology Criteria for adverse events (CTCAE).